Topical Ruxolitinib Evaluation in Vitiligo Study 1 (TRuE-V1)

Completed · Phase 3

Conditions studied: Non-segmental Vitiligo

In brief

The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in adolescent and adult participants with non-segmental vitiligo for whom total body involved vitiligo area (facial and nonfacial) does not exceed 10% body surface area (BSA).

Key facts

Study ID
NCT04052425
Run by
Incyte Corporation
People needed
330
Starts
2019-09-20
Expected to finish
2021-10-21
Last updated by the study team
2025-08-22

Who can join

Age: 12 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.